Shares of AstraZeneca AZN rose 1.5% in pre-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share fell 5.05% over the past year to $0.94, which beat the estimate of $0.44.
Revenue of $6,578,000,000 rose by 2.68% year over year, which missed the estimate of $6,650,000,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
AstraZeneca hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: Nov 05, 2020
Time: 06:45 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/bwnkvaid
Recent Stock Performance
Company's 52-week high was at $64.94
52-week low: $36.15
Price action over last quarter: Up 0.18%
Company Description
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
